Combination therapy for advanced stomach or esophagus cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs for advanced stomach or esophagus cancer that hasn't been treated much. The goal is to see if this combination helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have stomach cancer, or cancer where the stomach meets the food pipe, or cancer of the food pipe that has spread or cannot be removed with surgery.
- Your cancer must be a type that is not HER2-positive and is microsatellite stable (a specific lab test result).
- You can have had no more than one previous treatment for cancer that has spread.
- You need to be generally active and able to take care of yourself (performance status 0 or 1), per the trial's criteria.
- Your blood counts, liver, and kidney function must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
This trial tests a new drug combination for people with advanced stomach or gastroesophageal junction cancer that has grown after earlier treatment. It aims to see if adding these drugs can help shrink tumors or slow the disease.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
Hear when a new Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.